Dig Deeper, Go Further.
…with our Value, Pricing & Access experts.
Join us at ISPOR Europe.
We’re a proud sponsor and exhibitor at this November’s ISPOR Europe in Copenhagen, Denmark.
Hear from one of our experts.
Where to find us.
C2-011
Our booth
20+
Featured posters
1
Sponsored educational symposium
The poster titles you might want to visit.
Don’t miss out on the poster sessions throughout the duration of the conference for a chance to view some of our recent work across a range of topics.
Here are some of our titles
- How immunotherapies have altered the future of cancer treatment: Patients living longer, healthier lives.
- Carer burden: Is HTA helping or harming the gender health gap?
- Utilisation of RWE in HTA appraisals in England, Scotland, Germany and France.
- The use of qualitative methods in the NICE HST deliberative process.
- The impact of the disease severity modifier on NICE technology appraisal decisions.
- Natural language processing to support the abstract selection during systematic literature review.
- Comparisons of economic evaluation guidelines between Japan and six countries (England, France, Germany, Sweden, Canada, and Australia).
- Retrospective analysis of the French early access experience following the 2021 reform.
- EUnetHTA’s HTA Core Model®: A critical assessment and future outlook.
- Review of HTA evaluation for gene therapies and their future implications in Europe.
- Reimbursement of CAR-T cell therapies in Europe: Key challenges from precedents and lessons for future.
- Evolution of timeframes within the overall time-to-market since marketing authorisation for new innovative-presumed products in France since the first published economic opinion.
- CAR-T cell therapies pathway: Evolution of management and of costing methodology in the French cost-effectiveness analyses (CEA) landscape.
- Impact of the 2020 update of the French HAS guidelines for economic evaluation on the economic opinions issued by the Economic Evaluation and Public Health Committee (CEESP).
- Recent advances in voluntary European cross-border collaborations in joint HTA and drug pricing/procurement.
- The role of EUnetHTA 21 in promoting patients’ engagement.
- A comparison of the UK and Australian interim value sets for the Weight-Specific Adolescent Instrument for Economic Evaluation (WAItE).
- Evolution of French efficiency opinions published by the Economic Evaluation and Public Health Committee (CEESP) in oncology.
- Evolution of French economic opinions published by the Economic Evaluation and Public Health Committee (CEESP).
- Analysis of the impact of early access decisions on pricing and reimbursement decisions in France.
- Health technology assessment requirements: Sensitive to bacteriophage products or too resistant to change?
About the sponsored educational symposium.
Putnam is partnering with AstraZeneca and Daiichi-Sankyo, who are sponsoring an educational symposium: ‘Is there any hope for the Value of Hope?’
The expert panel will include:
- Moderator, Louise Longworth, PhD, Putnam
- Meindert Boysen, PharmD, NICE
- Lou Garrison, PhD, University of Washington
- James Ryan, MSc, AstraZeneca
- and Bettina Ryll, MD, PhD, Melanoma Patient Network Europe
Join us in this informative session to learn more about The Value of Hope.
Bridging Science & StrategyTM.
We are a leading scientific and strategic consulting partner that helps the global life science community make confident decisions, build value, and bring life-changing innovations to clinicians and patients.
Latest Insights.
-
Read more
Medicare price negotiation: Putnam’s round one picks
This paper outlines predictions regarding drugs likely to be impacted by Medicare Price Negotiation in 2026 and implications in subsequent years.
-
Read more
HTA evidence generation and preparedness for a novel oncology treatment
Our client needed successful HTA evidence packages and submissions to achieve reimbursement across Europe for an innovative oncology treatment.
-
Read more
Early value insights to drive value definition and evidence need to produce TrPP
The client wanted to understand the key drivers of value for the new treatment for sleep disorders including narcolepsy.
-
Read more
The Inflation Reduction Act: A tale of two drugs
Putnam is developing tools and insights to help manufacturers assess and realize opportunities and mitigate risks from Inflation Reduction Act.
Leaders attending.
Navigate this carousel with the arrows.
Get in touch.
Looking to get in touch with an expert or team member? Tell us how we can help.